Premium
Lymph node involvement: Positive about the role of the recurrence score in estrogen‐driven breast cancer?
Author(s) -
Kalinsky Kevin,
O’Regan Ruth M.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31814
Subject(s) - medicine , breast cancer , observational study , oncology , lymph node , chemotherapy , randomized controlled trial , estrogen , clinical trial , population , cancer , environmental health
It remains unclear whether there is clinical utility for withholding chemotherapy in HR+/HER2‐, node‐positive breast cancer based upon the 21‐gene Recurrence Score. While we await the results from randomized, phase III trials, this editorial addresses additional observational data that suggest there may be a role for this genomic assay in this patient population.